Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Life-sciences company Verona Pharma has signed a contract with LAB Research to start formal safety evaluation studies of its lead compound, RPL554, a novel long-acting bronchodilator/anti- inflammatory molecule.
Subscribe to our email newsletter
RPL554 is being developed for the treatment of hay fever and asthma, which are among the most prevalent respiratory diseases in the industrialised world.
According to Verona Pharma, the market for the treatment of these diseases is estimated to be some US$20 billion. Many of the available treatments have either unwanted side effects or limited effectiveness, creating a medical need in this market that the company is working to meet.
The results from the preclinical studies will form the central part of the submission documentation to be delivered to regulatory agencies in order to obtain approval to conduct first-into-man clinical phase I and clinical proof-of-concept phase IIa studies.